Does Lineage Cell Therapeutics, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Lineage Cell Therapeutics, Inc. (LCTX) 43.1 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 91, returns on capital 0, balance-sheet safety 55, capital discipline 24.

How has LCTX's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 43.1 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Lineage Cell Therapeutics, Inc.

LCTX · Healthcare · $282.0M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power91

Median gross margin 93.9% over 9y, stable.

Returns on capital0

Median ROIC -47.8%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $1.16
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for LCTX yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale43.1 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — LCTX has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#201 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#199CTKB CYTEK BIOSCIENCES, INC.43.4 out of 100, Shallow moatShallow moat
#200CDNA CAREDX, INC.43.2 out of 100, Shallow moatShallow moat
#202EBS EMERGENT BIOSOLUTIONS INC.43.1 out of 100, Shallow moatShallow moat
#203PYXS Pyxis Oncology, Inc.43.1 out of 100, Shallow moatShallow moat

Compare LCTX with its nearest peers →All Healthcare companies on the Index →

Common questions about LCTX

Does Lineage Cell Therapeutics, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Lineage Cell Therapeutics, Inc. (LCTX) 43.1 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 91, returns on capital 0, balance-sheet safety 55, capital discipline 24.
How has LCTX's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 43.1 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows LCTX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/LCTX"
  width="340" height="150" style="border:0"
  title="LCTX Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell LCTX. See the disclaimer.